Objective：To describe the preparation process of domestic carrier -free lutetium［¹⁷⁷Lu］and the method for labeling of ¹⁷⁷Lu with 1，4，7，10-tetraazacyclododecane-1u-，4，7，10-tetraacetic acid conjugated Tyr3-octreotide（DOTA-TOC），and to explore the safety and efficacy of the preliminary clinical application of domestically produced ¹⁷⁷Lu-DOTA-TOC. Methods：Domestic carrier-free lutetium［¹⁷⁷Lu］was prepared by multistage sequential isolation and purification，and fully automated modular labeling was used to synthesize ¹⁷⁷Lu -DOTA -TOC. The data of 4 patients with neuroendocrine neoplasms（NEN）in Naning Hospital Affiliated to Nanjing Medical University who only received domestic carrier-free lutetium［¹⁷⁷Lu］labeled DOTA-TOC peptide receptor radionuclide therapy （PRRT）were retrospectively analyzed. Results：The domestic carrier-free lutetium［¹⁷⁷Lu］had good quality control，with copper（Cu）< 0.01，zinc（Zn）<0.01，iron（Fe）<0.01，lead（Pb）<0.15，and thulium（Yb）undetectable，radiochemical purity >99%，and bacterial endotoxin <2 EU/mL. The yield of domestic automated labeling of ¹⁷⁷Lu-DOTA-TOC was（98.85±0.97）%，and the specific activity of the product was（80.96 ± 7.47）GBq/μmol. Sterility and endotoxin tests of the labeled product met the specified standards，and the ethanol content in the labeled product was 0，with a radiochemical purity greater than 99%. Among the 4 patients who received only domestic ¹⁷⁷Lu-DOTA-TOC only，1 patient showed almost complete disappearance of the primary and metastatic lesions after only one treatment，while another patient experienced grade 3 bone marrow toxicity one month after treatment，which recovered to normal after three months. None of the patients showed renal toxicity. Conclusion：Domestic carrier-free lutetium［¹⁷⁷Lu］labeled DOTA-TOC meets quality control standards，has a high yield，good safety，and tolerability，and has good therapeutic efficacy for patients with inoperable NEN. The domestication and large-scale production of carrier-free lutetium［¹⁷⁷Lu］will promote the integrated development of nuclear medicine diagnosis and treatment in China.